The US research-based industry group The Pharmaceutical and Research Manufacturers of America (PhRMA) is continuing to advocate for broad debate around reforms to Japan’s healthcare and drug reimbursement pricing systems, as it seeks to create an environment it sees as conducive to sustainable innovation, patient access to new drugs and economic benefits.
While many of the themes are familiar, one particular emphasis this year was a healthcare innovation roundtable, under which the group facilitated a discussion between executives from the Boston, MA...